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Background: Acute opioid tolerance (AOT) and opioid-induced hyperalgesia (OIH) are undesirable effects of
opioids that have been reported in both animals and humans. However, the development of AOT and OIH in cases
of potent, short-acting μ-opioid receptor agonist remifentanil administration remains controversial. It has been
suggested that the emergence of AOT and OIH by remifentanil could be dose and infusion duration dependent,
i.e., low dose and short infusions may lead to negative results. In this study, we determined whether AOT and OIH
could be elicited by prolonged, continuous administration of remifentanil at maximally tolerable doses in C57BL/6
mice.
Results: The analgesic effects of continuously administered remifentanil [by short (1 h) and prolonged (4 h)
intraperitoneal infusions] were studied. These experiments involved repeated measurements of thermal thresholds
during remifentanil administration. Therefore, particular attention was paid to prevent cumulative tissue injury,
which could mimic pronociceptive effects of remifentanil. To exclude the possibility of pseudoAOT during infusion,
we used brief cooling of all ipsilateral hindpaws that exhibited analgesic response. Thermal thresholds remained
steadily elevated over a 1-h period during continuous administration at infusion rates of 120, 180, and 240 mg/kg/h,
which indicated no AOT development. To exclude the possibility of pseudoOIH after infusion, intact contralateral
hindpaws were used for all postinfusion threshold measurements. Thermal thresholds at each infusion rate returned to
the baseline values within 15 min after the termination of the administration. They did not decrease below the
baseline values during 1 h following infusion, which indicated no OIH development. Similar threshold dynamics were
also observed for thermal and mechanical testing modalities in animals infused at 120 mg/kg/h for 4 h as well as in
animals with rapidly attained and maintained maximum analgesia for 3 h.
Conclusions: These results suggest that neither intra-infusion AOT nor postinfusion OIH develops in mice receiving
continuous remifentanil when the possibility of cumulative tissue injury mimicking AOT or OIH is carefully avoided.
Keywords: Opioid, Remifentanil, Thermal thresholds, Mechanical thresholds, Analgesia, Hyperalgesia, Hypersensitivity,
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Acute opioid tolerance (AOT) is defined as an increase
over time of the dose required to maintain adequate anal-
gesia in patients receiving opioid medication for the treat-
ment of pain in clinical settings [1,2]. At the same time,
opioid-induced hyperalgesia (OIH) is defined as a state of
nociceptive sensitization, which becomes apparent after* Correspondence: hishii@med.niigata-u.ac.jp
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reproduction in any medium, provided the oropioid exposure in clinical settings [1,2]. OIH is character-
ized by a paradoxical response whereby a patient receiving
opioids for pain treatment may have an increased sensitiv-
ity to pain.
In animal behavioral studies, AOT is observed as the
analgesic potency of an opioid that is rapidly reduced
(i.e., within the first several hours) over time. Such re-
ductions can be demonstrated by the attenuation of the
potentiating effect of opioids on the immobilizing effects
of inhaled anesthetics [3-5]. AOT is described as an an-
algesic opioid effect that diminishes over time during its. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Dose-effect curves for remifentanil determined by
thermal and mechanical nociceptive assays. (A) Hotplate test. The
ED50 was 16.0 mg/kg (n = 8); the doses were 2, 4, 8, 16, and 32 mg/kg.
(B) Plantar test. The ED50 was 35.7 mg/kg (n = 9); the doses were 8, 16,
32, and 64 mg/kg. (C) Randall-Selitto test. The ED50 was 6.9 mg/kg
(n = 11); the doses were 2, 4, 8, 16, and 32 mg/kg. The data are
presented as percent maximal possible effect (%MPE) ± SEM.
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sensitivity to painful stimuli immediately after opioid ad-
ministration [6,7]. Regarding these pronociceptive opioid
effects, some behavioral studies have shown controver-
sial results. For example, one study demonstrated that
OIH did not develop immediately following repeated
fentanyl injections, whereas nociceptive thresholds were
paradoxically decreased on the following day in the
fentanyl-treated animals [8]. Another study demon-
strated that while prolonged infusion of remifentanil
could induce pain hypersensitivity after an infusion (a
typical OIH reaction), no reduction of analgesic effect by
remifentanil (a typical AOT reaction) was documented
during this infusion [9].
Remifentanil, a potent, ultra-short acting μ-opioid re-
ceptor agonist, has been gaining popularity in clinical
anesthesia. In humans, there are several reports that
intraoperative remifentanil can be associated with the de-
velopment of AOT, which is evidenced by an increased
post-operative opioid consumption [10,11]. In contrast,
there are also negative reports that intraoperative
remifentanil does not cause AOT [12,13]. The existence of
AOT and OIH in healthy volunteers remains controversial
[14-17].
Several studies have indicated that AOT and OIH
could be dose and infusion duration dependent [4,9].
Additionally, it has been suggested that studies reporting
negative results using remifentanil could have used low
cumulative doses of remifentanil [18].
The purpose of the present study was to clarify the devel-
opment of AOT and/or OIH with a continuous infusion of
remifentanil administered at analgesic and maximally toler-
able doses in mice. Although most basic pain research on
opioids has been performed in rats, mice were chosen in
this study as a research model to evaluate pronociceptive
effects of remifentanil because of the availability of mouse
transgenic knockouts that can be employed to elucidate the
molecular mechanisms of opioid action [19]. This study
provided evidence arguing against the existence of AOT
and OIH following remifentanil exposure in mice.
Results
Previous studies that have used an intravenous route for
remifentanil administration reported analgesic effects when
remifentanil was administered in a μg range. However, our
preliminary experiments indicated that such doses of
remifentanil were ineffective by intraperitoneal adminis-
tration. Therefore, we performed dose-effect studies by
thermal and mechanical nociceptive assays to determine
the analgesic potencies of intraperitoneally administered
remifentanil, and the results are displayed in Figure 1. The
ED50 values for the hotplate, plantar, and Randall-Selitto
tests were 16.0, 35.7, and 6.9 mg/kg, respectively. Like other
opioids, remifentanil also caused behavioral alterations,
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of the tail), when administered at doses of 8–32 mg/kg and
akinesia and muscular rigidity when administered at doses
exceeding 100 mg/kg.
Next, we evaluated the analgesic effect of continuous
remifentanil infusion. An infusion was administered via
an indwelling intraperitoneal catheter, during which the
experiments would normally require animal restraint.
However, restraint was avoided by performing the infu-
sion under sevoflurane sedation. To exclude the possibil-
ity of sevoflurane (1.5% atm) affecting the sensory
thresholds, we concurrently performed a control experi-
ment with no remifentanil in sevoflurane-sedated mice
(Figure 2). As indicated in Figure 2, prolonged inhalation
of sevoflurane had no effect on the thermal withdrawal
thresholds, which remained unchanged for all 3 hours of
the experiment (P = 0.2858, one-way ANOVA). This
finding was consistent with a previous report that indi-
cated no sevoflurane-induced effect on sensory thresh-
olds [7].
The results of the constant-rate infusion experiments that
were performed over a 60-min period using the plantar test
are shown on Figure 3. Initially, we used a 1-h remifentanil
infusion rate that was calculated based on the remifentanil
ED95 value determined by the plantar test (59.3 mg/kg),
and on the duration of a single bolus i.p. injection of
remifentanil that did not exceed 15 min (60 mg/kg/15
min × 4 = 240 mg/kg/h). The withdrawal latencies increased
in a dose-dependent manner during the remifentanil infu-
sion. A rate of 240 mg/kg/h reached a peak effect approxi-
mately 15 min after the start of infusion (Figure 3A). The
effects of 180 and 120 mg/kg/h infusions increased grad-
ually and reached their maximum effects at 30 and 60 min
after the start of infusion, respectively. The withdrawal la-
tencies at rates of 120 and 180 mg/kg/h were not signifi-
cantly different from the latency that was induced by
240 mg/kg/h at 60 min (Figure 3B). The withdrawalFigure 2 Thermal thresholds measured by plantar test under
sevoflurane anesthesia/sedation. Four mice inhaled 1.5% atm
sevoflurane for 3 h. The latencies did not significantly change
throughout the experiment (P = 0.2858, one-way ANOVA).latencies did not decline during any infusion, which indi-
cated no development of AOT. The analgesic effect of
remifentanil was short lasting after terminating the infu-
sion. The latencies for all of the infusion rates returned to
the basal values within 15 min after the termination of the
infusion and did not decrease below the basal values during
the 1-h postinfusion period, which indicated no develop-
ment of OIH.
Subsequently, we examined the effect of prolonged
remifentanil infusions. Preliminary experiments demon-
strated that prolonged infusions of remifentanil at rates
greater than 120 mg/kg/h could result in the develop-
ment of muscular rigidity, respiratory depression, and
eventually lead to death. The mortality rate at 180 mg/
kg/h for 3 h was 50% (6/12). Therefore, to avoid the le-
thal side effects of prolonged remifentanil administra-
tion, we examined the effect of prolonged 120 mg/kg/h
remifentanil infusion on thermal and mechanical thresh-
olds (Figure 4). With this infusion rate, the effect of
remifentanil increased gradually, and maximum anal-
gesia was reached 1 h after the initiation of infusion. All
mice could safely complete the experiment; no lethality
was observed. The measured thresholds did not decline
during the infusion, which indicated no development of
AOT. The measured thresholds returned rapidly to the
basal values after completion of this regimen and did
not decrease below basal values during the next hour
postinfusion, which indicated no development of OIH.
In another experiment, to rapidly attain and maintain
analgesia at a maximum level while avoiding lethality,
we examined the effect of a tapered remifentanil infu-
sion on thermal thresholds. As shown in Figure 5, this
infusion was initiated at 240 mg/kg/h for 30 min and
subsequently reduced to 180 mg/kg/h for 30 min, with a
final rate of 120 mg/kg/h that was maintained for 2 h.
The maximum effect could be maintained for 3 h with-
out causing lethality. With this regimen, the measured
thresholds remained elevated during the infusion and
did not decrease below the baseline levels after the ter-
mination of the infusion, which indicated no develop-
ment of either AOT or OIH even when the maximal
analgesic effect of remifentanil was sustained for 3 h.
Discussion
Although there are numerous reports of the existence of
AOT and OIH in rodents, human studies have produced
conflicting results. It is unclear what accounts for the
equivocal results in humans or the differences between
humans and animals. Several articles have reviewed the
methodological and theoretical issues with respect to
discrepancies [2,18,20]. It has been suggested that meth-
odological issues could lead to conflicting results. These
issues, which could lead to a crucial misinterpretation,
were administration dose and duration. There is also a
Figure 3 Effect of short-term (60 min) remifentanil infusions on thermal thresholds measured by plantar test. (A) Time course. The
withdrawal latencies increased in a dose-dependent manner. During the infusion, all of the withdrawal latencies were significantly different from
the baseline values except at 15 min with an infusion rate of 120 mg/kg/h. (B) A comparison of the withdrawal latencies at each time point. At
60 min, the maximum analgesia was reached with all of the infusion rates. The withdrawal latencies at rates of 120 and 180 mg/kg/h were not
significantly different from the latency induced by 240 mg/kg/h at 60 min. The data are expressed as the mean ± SEM; n = 8 mice for all of the
groups. *P < 0.05 vs. baseline; #P < 0.01, ##P < 0.05 vs. 240 mg/kg/h (one-way ANOVA followed by Dunnett’s test).
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petitive and potentially tissue-damaging nature of the
stimuli used to determine the threshold during opioid
infusion.
The administration dose of this study should have been
more than sufficient to elicit AOT and OIH. We found
that with the intraperitoneal route, attaining analgesia by
remifentanil required infusion rates in the range of mg/
kg/h. This is in contrast to several other studies that
reported analgesia by remifentanil when administered inμg/kg/h range by the intravenous route [3-5]. The intra-
peritoneal injection of remifentanil may require higher
doses because of the esterase-dependent metabolism of
this drug. Remifentanil is rapidly metabolized by non-
specific blood and tissue esterases. The hydrolysis of
remifentanil by esterases appears to occur at a limited rate
in blood and more rapidly in tissues. In fact, Davis et al.
reported that tissue metabolism was the main factor in
remifentanil hydrolysis [21]. Because the majority of
remifentanil is metabolized in tissues, its intraperitoneal
Figure 4 Effect of a prolonged (4 h) remifentanil infusion at a constant rate of 120 mg/kg/h on nociceptive thresholds. (A) The thermal
thresholds measured by plantar test (n = 8). (B) The mechanical thresholds determined by Randall-Selitto test (n = 11). The data are presented as
the mean ± SEM. *P < 0.05 vs. baseline (one-way ANOVA followed by Dunnett’s test).
Ishii et al. Molecular Pain 2013, 9:11 Page 5 of 9
http://www.molecularpain.com/content/9/1/11injection and immediate, direct exposure to tissue
esterases might require significantly higher doses of
remifentanil compared with that of an intravenous
injection. The possibility of accelerated local tissue
cleavage of remifentanil, a carboxylic acid methyl ester,
upon its intraperitoneal administration is also supported
by the fact that mesothelial cells of the peritoneum are
known to contain high levels of carboxylesterase [22].
In this study, we selected an alternative parenteral route
of remifentanil administration via a catheter placed in the
intraperitoneal space, whereas most animal studies of
remifentanil analgesia used rats and an intravenous route
of drug administration. This selection was due to technical
difficulties related to tail vein catheterization in mice
weighing < 30 g. As it was previously mentioned, although
this route required unconventionally high remifentanildoses, such doses were necessary and also sufficient to
elicit powerful analgesic effect, which occurred for single
bolus injections at postinjection times comparable with
other anesthetic agents administered via this route
[23-25]. During the 4-h 120 mg/kg/h infusions, the devel-
opment of a robust analgesic effect against thermal stimuli
required certain time, whereas an analgesic effect was
quite rapidly attained against mechanical stimuli. This
could be because of the more damaging nature to living
organisms of thermal stimuli compared with mechanical
ones. Additionally, in a separate set of experiments, we
used a tapered remifentanil infusion to rapidly attain max-
imum analgesic effect of remifentanil against thermal stim-
uli. However, even in this setting, neither AOT nor OIH
was observed. Thus, it appears unlikely that a somewhat
“slow” intraperitoneal route per se could have precluded
Figure 5 Effect of a prolonged (3 h) and tapered remifentanil infusion on thermal thresholds measured by plantar test. The infusion was
started at a rate of 240 mg/kg/h that was reduced to 180 mg/kg/h at 30 min and continued at 120 mg/kg/h at 60 min until the end of the infusion.
The data are expressed as the mean ± SEM, n = 6. *P < 0.05 vs. baseline (one-way ANOVA followed by Dunnett’s test).
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some studies that have reported acute pronociceptive ef-
fects of remifentanil have utilized an even slower subcuta-
neous route for its continuous infusion [7,26].
The duration of the remifentanil administration also
should have been sufficient to elicit pronociceptive ef-
fects of remifentanil should they develop. AOT in ani-
mal studies is typically investigated during continuous
infusion over 2–3 h, whereas OIH is usually assessed
within 1 h postinfusion [3-6,9,27]. Consequently, the
same parameters were adopted as those previously
reported: remifentanil was infused continuously for 3–4 h,
and the effects were investigated for 60 min postinfusion in
the current study. However, in this study, despite a suffi-
cient duration and full analgesic effect of the remifentanil
infusion, we could not document the development of AOT
or OIH.
Remifentanil infusions were performed under sedation
with 1.5% sevoflurane, and the possibility of this anes-
thetic preventing the development of AOT or OIH
should be considered. This appears to be relevant be-
cause one study has previously suggested that sevo-
flurane can prevent the development of hyperalgesia in
rats that received four repeated subcutaneous injections
of 60 μg/kg fentanyl [28]. However, the possibility of
sevoflurane affecting the results of our study is unlikely,
because a prevailing number of reports have demon-
strated the development of pronociceptive effects of
remifentanil in rats or mice despite the fact that theywere inhaling sevoflurane at concentrations compara-
ble or even greater than those used in this study
[3-5,7,26,29,30]. The unlikely remifentanil-sevoflurane
interaction is further supported by the fact that, com-
pared with other inhalational anesthetics, sevoflurane
has only a minimal inhibitory effect on NMDA receptors
[31], which are considered to be involved in the develop-
ment of opioid-related hypersensitivity [32].
When nociceptive thresholds are repeatedly measured
in a situation in which protective withdrawal reflexes are
impaired or abolished by opioid administration, the pos-
sibility of cumulative tissue injury manifesting as AOT
or OIH should be carefully excluded [33]. In our experi-
ence, even limiting exposure to heat by cutoff points set
at ≥2-fold the threshold (e.g., 10 sec vs. baseline of ≈ 4
sec as was performed here) if left unattended can result
in thermal injury. This is especially likely to occur
with repetitive testing protocols. Additionally, with the
testing-during-the-infusion protocols, a longer opioid in-
fusion is equivalent to more injury to the stimulated site.
Comparison with saline controls in such a situation
would be inadequate because withdrawal responses in
the absence of opioids are preserved throughout the ex-
periment, meaning that no injury is inflicted.
What differentiated our study from other studies that
reported pronociceptive effects of remifentanil is the
careful attention and exclusion of the possibility of such
cumulative tissue damage, which could occur due to re-
petitive nociceptive testing if performed under the
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cause of AOT and OIH was carefully avoided. Thermal
tissue injury, which could have been misinterpreted as
AOT during the infusion, was avoided by cooling of the
ipsilateral hindpaws after each threshold determination
indicative of analgesic response (See Methods section).
Any residual thermal or mechanical tissue damage,
which could have manifested after the infusion in the ip-
silateral hindpaws as OIH, was avoided by using the
contralateral hindpaws for postinfusion measurements.
Using contralateral hindpaws was possible because of
the systemic nature of OIH that, if it develops, can be
detected at any stimulated site of the body. Thus, having
carefully excluded the possibility of artificially induced
and opioid-unrelated increase in pain sensitivity, we have
found no evidence for the development of remifentanil-
induced pronociceptive effects in our experimental
mouse model.
Conclusions
Continuous infusion of remifentanil did not induce
AOT and OIH as evidenced by a steady analgesic effect
of remifentanil during infusion and the uneventful
normalization of nociceptive thresholds after the termin-
ation of its infusion. Our results in mice support most
human data that indicate no development of AOT and
OIH after remifentanil administration. These findings
also indicate a need for critical reevaluation of experi-
mental protocols that are aimed to examine prono-
ciceptive effects of opioids and involve repetitive thermal
testing during opioid administration in animals.
Methods
Animals
This study was approved by the Animal Research
Committee of the Niigata University Graduate School of
Medical and Dental Sciences in Niigata, Japan. All of the
procedures were performed on adult (8–14 weeks of
age) male C57BL/6 mice, weighing 17–22 g at 8 weeks.
The animals were housed in cages (4–5 mice per cage)
under a standard 12-h light/dark cycle with food and
water available ad libitum. The temperature of the test-
ing room was kept at 24 ± 2°C, and the experiments
were conducted between 09:00 and 18:00. All of the ex-
periments except the hotplate test were performed
under light sevoflurane anesthesia/sedation. The mice
used in the hotplate experiment were habituated to the
testing room environment for 1 h (including 15 min of
placing the mice on the turned-off hotplate apparatus)
for three consecutive days before the test to become qui-
escent and allow for reliable data collection [24]. All of
the mice were used in several experiments and were left
undisturbed for ≥1 week after each experiment to pro-
vide sufficient time for recovery. In each experimentalsession, one stimulus modality (thermal or mechanical)
and one dosing regimen were used. All efforts were
made to minimize animal suffering and the number of
animals used.
Drugs
Remifentanil (UltivaW) and sevoflurane (SevofraneW)
were purchased from Janssen Pharmaceutical (Tokyo,
Japan) and Abbott Japan (Tokyo, Japan), respectively.
Remifentanil was dissolved in normal saline (0.9% NaCl).
Determination of analgesic range of intraperitoneally
administered remifentanil
The analgesic effects of single bolus intraperitoneal in-
jections of remifentanil were evaluated by measuring
the thermal and mechanical pain thresholds by hot-
plate, plantar, and Randall-Selitto tests. Remifentanil
was injected in a volume of 2.5 ml/kg using a 30-
gauge needle after an aspiration test. For the hotplate
test, the doses were 2, 4, 8, 16, and 32 mg/kg. For the
plantar test, the doses were 8, 16, 32, and 64 mg/kg.
For the Randall-Selitto test, the doses were 2, 4, 8, 16, and
32 mg/kg. The preliminary experiments established that
the analgesic effect of remifentanil first became evident
approximately 2 min postinjection, and 3–4 min post-
injection was a time after which the maximum response
to intraperitoneal remifentanil was achieved. After deter-
mining the basal latencies, thermal and mechanical laten-
cies were measured 3 min after each dose injection and at
least 15 min were allowed before the injection of the next
dose. The analgesic data are presented as the percentage
of maximal possible effect (%MPE) according to the fol-
lowing formula [34]:
%MPE ¼ post drug threshold–pre drug thresholdð Þ=
cutoff threshold–pre drug thresholdð Þ  100%
The 50% analgesic doses (ED50) were calculated by
performing nonlinear regression analyses.
Continuous infusion of remifentanil
Analgesic effects of continuous remifentanil administra-
tion on thermal and mechanical thresholds were studied
during short (1 h) and prolonged (3 or 4 h) remifentanil
infusions. For this purpose, the mice were individually
placed in an induction chamber into which 5% atm
sevoflurane in a continuous oxygen flow of 1 L/min was
administered. After induction, the mice were transferred
to individual small plastic chambers that were connected
to a vaporizer and 100% oxygen source as described pre-
viously [23]. The concentrations of sevoflurane were
continually monitored using an infrared gas analyzer
(Capnomac Ultima, Datex Instrumentarium, Helsinki,
Finland). Rectal temperatures were determined using a
digital thermometer (TD-300, Shibaura Electronics,
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lating hot water and placed below the chambers was
used to actively maintain the body temperature between
36–38°C. The mice were kept under spontaneous venti-
lation during the entire experiment.
The implantation of an intraperitoneal catheter for
continuous infusion was performed under 3% atm
sevoflurane. The abdominal wall was gently lifted, and a
20-gauge Tuohy needle (Perifix, B Braun, Tokyo, Japan)
was inserted in the mid abdomen after disinfection with
chlorhexidine and carefully advanced for approximately
1 cm. A catheter for continuous infusion was introduced
through the needle for approximately 2 cm into the in-
traperitoneal cavity. After removal of the needle, the
catheter was fixed to the skin with 5–0 silk suture.
All threshold determinations, including those before,
during, and after the infusions, were performed under
sevoflurane administered at a sedative concentration of
1.5% atm. After a 15-min equilibration period for sevo-
flurane, the intraperitoneal administration of remi-
fentanil was started and kept constant at 0.2 ml/h by an
infusion pump (FP-1000, Melquest, Toyama, Japan). The
thermal and mechanical thresholds were determined on
both hindpaws before the infusion, on the ipsilateral
hindpaws during the infusion, and on the contralateral
hindpaws after the infusion. During the infusions, re-
peated brief cooling of thermally stimulated ipsilateral
hindpaws was used to avoid the cumulative thermal in-
jury that could mimic AOT (see Behavioral Testing:
Thermal sensitivity). Additionally, to exclude a possibil-
ity of any residual thermal injury mimicking OIH after
the infusion, contralateral hindpaws were chosen for
postinfusion thermal threshold measurements. During
preliminary experiments, repetitive mechanical stimula-
tion was shown to be less damaging and did not result in
decreased thresholds on the ipsilateral side postinfusion
compared with thermal stimuli. However, for reasons of
better experimental reliability, postinfusion measurements
of mechanical thresholds were also performed on contra-
lateral hindpaws. The baseline thermal and mechanical
thresholds were averaged bilateral latencies that were de-
termined 30 and 15 min prior to the commencement of
the infusion (0 min). The latencies were measured every
15 or 30 min during and after the infusion for short-term
and prolonged infusions, respectively.
Behavioral testing: thermal sensitivity
Thermal sensitivity was evaluated by a hotplate test in
conscious mice and a plantar test in sedated mice. An
apparatus consisting of an acrylic cage and temperature-
controlled plate was used for the hotplate test (Hotplate
analgesia meter, IITC/Life Science Instruments, Woodland
Hills, CA, USA). The mice were placed on a 52°C hotplate,
and reaction times to lick the hindpaw or jump wererecorded. A maximum cutoff time of 60 sec was used in
the absence of a response.
The plantar test was conducted using a Hargreaves
plantar apparatus (Ugo Basile Inc., Varese, Italy) [35].
During the test, only the hindpaws were exposed while
the mice were kept in the anesthetic chambers. Thermal
sensitivity was assessed by measuring hindpaw with-
drawal latencies to a radiant heat stimulus. The time
until the withdrawal of the hindpaw was automatically
recorded. A maximum cutoff time of 10 s was used in
the absence of a response. Our preliminary experiments
demonstrated that repetitive thermal stimulation per-
formed during a 180 mg/kg/h 1-h remifentanil infusion
when protective withdrawal reflexes were absent because
of opioid analgesic effect could cause cumulative burn
injury that was evident by erythematous changes in the
plantar skin and paw swelling and manifested as hyper-
algesia (average 1-h postinfusion latency of 2.7 ± 0.1,
n = 6, vs. an average baseline latency of 4.6 ± 0.8, n = 6,
P = 0.0210, paired t-test). Therefore, in subsequent remi-
fentanil experiments, for all analgesic responses defined
for quick practical reference as latencies >6 s, we cooled
the stimulated hindpaws in ice-cold water for 2× the
measured latency to avoid cumulative burn injuries dur-
ing the infusion. The beneficial effects of immediate
cooling on the burn wounds have been well recognized
in the literature [36-40]. In this study, the absence of
thermal injury in the stimulated ipsilateral hindpaws was
confirmed by their careful visual inspection through-
out the experiment, during and after the remifentanil
infusion, and on the following day. The postinfusion
measurements were performed in the intact contralateral
hindpaws without cooling.
Behavioral testing: mechanical sensitivity
Mechanical withdrawal reflexes were evaluated by the
Randall-Selitto test in sedated mice [41]. Mechanical
pressure was applied to the hindpaws using a pressure
analgesia meter (MK-201D, Muromachi Kikai, Tokyo,
Japan). The application of pressure continued until the
mouse withdrew its hindpaw or the pressure reached
250 mmHg, which was established as a cutoff pressure
in the absence of a response.
Statistical analysis
Statistical analysis was performed by GraphPad Prism
software version 5.04 (GraphPad Software Inc., San Diego,
CA, USA). The responses at each time point during the
prolonged remifentanil infusions were compared with
baseline measures using repeated-measures one-way
ANOVA with Dunnett’s posttest. The differences between
the three remifentanil doses at different time points dur-
ing the 1-h infusion were analyzed by one-way ANOVA
followed by Dunnett’s posttest. All of the data are
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statistically significant.
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